Mitchell MD - Alpine Immune Executive CEO

ALPNDelisted Stock  USD 12.37  0.23  1.83%   

CEO

Mitchell MD is Executive CEO of Alpine Immune Sciences
Age 56
Phone206 788 4545
Webhttps://www.alpineimmunesciences.com

Alpine Immune Management Efficiency

The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.
Alpine Immune Sciences currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Alpine Immune Sciences has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpine Immune's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 8 records

CEO Age

Jon CongletonMineralys Therapeutics, Common
61
Amy MBATerns Pharmaceuticals
54
Fred JDIGM Biosciences
71
Richard CunninghamAnebulo Pharmaceuticals
53
Jeremy MBADay One Biopharmaceuticals
53
Daniel MBAAcumen Pharmaceuticals
54
Markus MDMonte Rosa Therapeutics
53
Faraz MBATenaya Therapeutics
51
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmuneinflammatory disorders, and other diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. Alpine Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people. Alpine Immune Sciences (ALPN) is traded on NASDAQ Exchange in USA and employs 142 people.

Management Performance

Alpine Immune Sciences Leadership Team

Elected by the shareholders, the Alpine Immune's board of directors comprises two types of representatives: Alpine Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpine. The board's role is to monitor Alpine Immune's management team and ensure that shareholders' interests are well served. Alpine Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpine Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
Temre Johnson, Head Communications
Remy Durand, Chief Officer
Andrew MD, Chief Officer
Paul Rickey, CFO, Senior Vice President Secretary
Stanford MD, President Development
Wayne Gombotz, Chief Officer
Mitchell MD, Executive CEO
Pamela Holland, VP Research
Wolfgang MD, Chief Officer
Christina Yi, Chief Officer

Alpine Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpine Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Alpine Stock

If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges